UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/700,274	11/03/2003	Joseph S. Podolski	07189.0014.DVUS02	9175
IP Prosecution HOWREY SIMON ARNOLD & WHITE, LLP Box No. 34 1299 Pennsylvania Avenue, N.W. Washington, DC 20004-2402			EXAMINER	
			PRYOR, ALTON NATHANIEL	
			ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			05/11/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/700,274	PODOLSKI, JOSEPH S.		
Office Action Summary	Examiner	Art Unit		
	ALTON N. PRYOR	1616		
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet wi	th the correspondence address		
A SHORTENED STATUTORY PERIOD FOR REL WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	E DATE OF THIS COMMUNIO R 1.136(a). In no event, however, may a r iod will apply and will expire SIX (6) MON atute, cause the application to become AB	CATION. eply be timely filed THS from the mailing date of this communication. EANDONED (35 U.S.C. § 133).		
Status				
Responsive to communication(s) filed on 28 2a) This action is FINAL . 2b) ▼ T Since this application is in condition for allow closed in accordance with the practice under	his action is non-final. wance except for formal matt			
Disposition of Claims				
4) Claim(s) 47-64 is/are pending in the applica 4a) Of the above claim(s) is/are witho 5) Claim(s) is/are allowed. 6) Claim(s) 47-51 and 53-64 is/are rejected. 7) Claim(s) 52 is/are objected to. 8) Claim(s) are subject to restriction and Application Papers 9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) are subjected to by the Exam	drawn from consideration. d/or election requirement. niner. accepted or b) □ objected to	•		
Applicant may not request that any objection to to Replacement drawing sheet(s) including the cornal The oath or declaration is objected to by the	rection is required if the drawing	(s) is objected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s	Summary (PTO-413) s)/Mail Date nformal Patent Application 		

DETAILED ACTION

Applicant's arguments, see paper, filed 6/28/05, with respect to the rejection(s) of claim(s) have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new grounds of rejections are made below. Previous rejections not addressed below have been withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 50-64 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The term "less than about" in claims 50-64 (specifically claim 50 line 2) is a relative term which renders the claim indefinite. The term "less that about" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Applicant should consider selecting either "about" and/or "less than". The selection(s) must be supported by the original disclosure to avoid new matter issues.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Art Unit: 1616

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 47-51,53-64 are rejected under 35 U.S.C. 103(a) as being unpatentable over Virag (USPN 5145852; 9/8/92), Kuhrts (US2002/0068365; 6/6/02), Fung et al (USPN 5646181; 7/8/97) and El-Rashidy et al (USPN 6121276; 9/19/00).

Virag teaches a formulation used to treat impotence comprising papavarine, 1mg/ml phentolamine and 33 ug of alprostadil (column 2 lines 64-68). It would have been obvious for an artisan in the field to administer a formulation comprising papaverine, phentolamine and alprostadil for the purpose of treating impotence.

With respect to the claimed buffer, the Examiner takes judicial notice according to MPEP 2144.03 that the optimal pH for papaverine solutions ranges from 2 to 2.8. Therefore, it would have been obvious to buffer the formulation taught by Virag near pH 3. According to Boesch 205 USPQ 215 (CCPA, 1980), it is obvious for an artisan to optimize amounts and ratios of ingredients.

Virag further does not teach a composition used to treat impotence comprising L-arginine and/or benzyl alcohol.

Kuhrts teaches that L-arginine enhances the production of nitrous oxide in a mammal so that impotence can be effectively treated (abstract, claims 1,2,23 and 24).

El-Rashidy et al teach that mannitol is an osmotic agent used in compositions to treat impotence.

Fung et al. teach that benzyl alcohols are used in formulations to treat impotence. Benzyl alcohol is vehicle for nitrate containing formulations. (abstract, column 4 lines 34-47).

Application/Control Number: 10/700,274 Page 4

Art Unit: 1616

It would have been obvious to modify the invention taught by Virag to include Larginine for the purpose of enhancing the production of nitrous oxide in the patient,
mannitol to control osmotic level of the patient and benzyl alcohol for the purpose of
aiding the delivery and penetration of the actives.

Claim Objection

Claim 52 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The prior art does teach or suggest instant invention comprising glycine.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALTON N. PRYOR whose telephone number is (571)272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/700,274 Page 5

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Alton N. Pryor/ Primary Examiner, Art Unit 1616